Clinical and molecular characteristics of mucosal signet-ring cell carcinoma in Helicobacter pylori-uninfected stomach

Mariko Kiso  
Hiroshima University Hospital

Yuji Urabe (✉ beyan13@hiroshima-u.ac.jp)  
Hiroshima University Hospital  https://orcid.org/0000-0003-0942-1541

Masanori Ito  
Hiroshima University Hospital

Kazuhiko Masuda  
Miyoshi Central Hospital

Tomoyuki Boda  
Hiroshima University Hospital

Takahiro Kotachi  
Hiroshima University Hospital

Kosaku Hata  
Chugoku Rosai Hospital

Naoki Yorita  
Hiroshima University Hospital

Naoko Nagasaki  
Hiroshima University Hospital

Madina Abdurahman  
Hiroshima University Hospital

Yuich Hiyama  
Hiroshima University Hospital

Shiro Oka  
Hiroshima University Hospital

Shinji Tanaka  
Hiroshima University Hospital

Kazuaki Chayama  
Hiroshima University Hospital

Research article

Keywords: Helicobacter pylori, uninfected, signet ring cell carcinoma, next generation sequence, smoking

Posted Date: May 8th, 2020
Abstract

Background: Gastric cancer develops even in *Helicobacter pylori*-uninfected patients and its typical histological feature is signet ring cell carcinoma (SRCC) within the mucosal layer. However, the biological characteristics of SRCC remain unclear. We aimed to clarify the pathological and genetic features of SRCC in *Helicobacter pylori*-uninfected patients.

Methods: Seventeen *Helicobacter pylori*-uninfected patients with mucosal SRCCs were enrolled and their clinicopathological characteristics were compared with those of *Helicobacter pylori*-infected patients with mucosal SRCCs. Seven SRCCs without *Helicobacter pylori* infection, including two invasive SRCCs, and seven *Helicobacter pylori*-positive SRCCs were subjected to a genetic analysis using next-generation sequencing.

Results: *Helicobacter pylori*-uninfected patients with mucosal SRCCs revealed male dominancy and a significantly higher prevalence of smokers among them as compared with the *Helicobacter pylori*-infected patients with SRCC. A CDH1 mutation (frame shift indel) was detected in one *Helicobacter pylori*-uninfected cancer not only in the mucosal SRCC but also in the invasive portion. A TP53 mutation was detected in one SRCC without *Helicobacter pylori* infection. In the control group, ARID1A and TP53 mutations were detected in one SRCC each. The C to A mutation, which is a characteristic smoking-induced mutation, was not found in any of the samples.

Conclusions: Some SRCCs in *Helicobacter pylori*-uninfected patients may have a malignant potential similar to that of SRCCs in *Helicobacter pylori*-infected patients. Smoking is not a main carcinogenic factor for the development of SRCCs.

Background

It is well recognized that *Helicobacter pylori* (*H. pylori*) infection is the main cause of gastric cancer development [1]. In Japan, we previously reported that over 99% of patients with gastric cancer had *H. pylori* infection [2], and another study reported a similar result [3]. However, gastric cancer may develop even in *H. pylori*-uninfected patients and its typical histological feature is signet ring cell carcinoma (SRCC) within the mucosal layer [4]. Endoscopically, SRCCs can be easily recognized as whitish depressed or flat lesions, and their prevalence and clinical importance have recently been increasing [5].

Previous reports have suggested that SRCCs in *H. pylori*-uninfected patients show a lower proliferative activity, few extensive spread, and slower progression, compared with SRCCs with *H. pylori*-infected patients [6]. The features of SRCCs in *H. pylori*-uninfected patients resemble those in patients with hereditary diffuse gastric cancer (HDGC), which is caused by a germline mutation of CDH1 [7]. In patients with HDGC, a large number of SRCCs can be detected; however, most of them show little tendency to invade into the submucosal layer. Therefore, it is controversial whether SRCCs in *H. pylori*-uninfected patients can invade into the submucosal layer. In addition, the pathogenesis of SRCCs in *H. pylori*-uninfected patients remains uncertain. Recently, Horiuchi *et al.* reported the implication of smoking in the disease pathogenesis of these patients, noting that their findings should be verified by other studies [8].

In the present study, we compared the clinical features of SRCCs between patients with and without *H. pylori* infection. Moreover, we investigated the genomic characteristics of these lesions to identify their biological characteristics and assess whether smoking may be involved in their pathogenesis.
Methods

Patients

We enrolled 19 consecutive patients with SRCC (17 with mucosal cancer and 2 with invasive cancer) without *H. pylori* infection who were diagnosed in Hiroshima University Hospital from 1998 to 2017. All the patients received endoscopic or surgical resection. The entire tumor was cut into parallel 2–4 mm-thick sections for investigation. Histological evaluation was performed according to the Japanese gastric cancer treatment guidelines [9]. Clinicopathological data was retrospectively reviewed from clinical records. The definition of *H. pylori*-negative subjects was judged by our criteria as described in a previous publication [2].

A total of 34 patients with *H. pylori*-positive SRCC diagnosed in the same period were enrolled as controls. This retrospective study was approved by the institutional review board and the ethics committees of Hiroshima University (No. E-1237) and was performed in accordance with the Helsinki Declaration and its later amendments.

Tissue capture and DNA extraction

In the experiments with next-generation sequencing, we randomly selected seven patients who were habitual smokers among both the *H. pylori*-negative and -positive SRCCs. Two invasive SRCCs (Case 5 and 6) were included in the *H. pylori*-uninfected group. In these two cases, the tumors were composed of a mucosal SRCC and a poorly differentiated adenocarcinoma (PDA) component in the deeper portion.

Pathologic tumor tissues were dissected from ten 10-µm-thick slides made from formalin-fixed paraffin embedded (FFPE) specimens, which were deparaffinized, stained, and dehydrated using the Arcturus® Paradise® PLUS Reagent System (Thermo Fisher Scientific, Waltham, MA, USA). Dissections were performed using a laser capture microdissection system (LMD 6500, Leica, Wetzlar, Germany), in accordance with the pathogenesis diagnosis. The DNA was extracted from these tissues using the GeneRead DNA FFPE kit (Qiagen, Valencia, CA, USA), and concentrations were determined using a Qubit® 1.0 fluorometer (Life Technologies, Carlsbad, CA, NY, USA). The quantity and quality of the FFPE-derived DNA samples were checked by calculating the normalized DNA integrity scores (ΔΔCq) via quantitative polymerase chain reaction (PCR) analysis using the Agilent NGS FFPE QC kit (Agilent, Santa Clara, CA, USA).

Target enrichment and next-generation sequencing

DNA extracted from tumors was fragmented into 150–200 bp portions by sonication using an S2 sonicator (6 min, 10% duty, intensity = 5, 200 cycles/burst; Covaris, Woburn, MA, USA) and used for library construction according to the manufacturer’s instructions. In all cases, 10 ng of DNA was prepared for sequencing. The exons of ten oncogenes (CDH1, TP53, ARID1A, KRAS, PIK3CA, ERBB3, FBXW7, TGFBR1, RHOA, and MAK2K1) were enriched using the SureSelectXT HS Custom panel (Agilent). The resulting pooled libraries were quality control-checked via the High Sensitivity D1000 ScreenTape system using the 2200 TapeStation instrument (Agilent). Sequencing was performed with paired-end reads via the HiSeq 2500 platform (Illumina, San Diego, CA, USA).

Variant detection

Sequencing reads were aligned to the hg19/GRCh37 reference sequence and analyzed using SureCall 4.0.1 (Agilent). PCR duplicates were removed and low-frequency mutations in template DNA molecules were detected using the molecular barcode system [10]. To identify variants in tumor samples, single sample analysis in SureCall 4.0.1 was used. The called variants were considered germline mutations if they were found in the dbSNP 137 or
TogoVar (https://togovar.biosciencedbc.jp) databases. The remaining mutations in cancerous tissues were considered to be candidate cancer-specific mutations. To reduce the false positive rate, we set the cutoff values for somatic mutation in cancerous tissues as follows: variant score > 0.3; minimum quality for base > 30; variant call quality > 100; allele frequency > 0.1; and number of reads supporting the variant allele > 3 (Supporting file 1).

**Statistical analysis**

All clinicopathological features were analyzed using the Chi-square test or Fisher’s exact test to compare categorical data and Student’s t test or Wilcoxon rank-sum test to compare continuous data. A p-value of < 0.05 was considered significant. All statistical analyses were performed using JMP® software (SAS International, Cary, NC. USA).

**Results**

*Comparison of clinical features between H. pylori-uninfected and -infected signet ring cell carcinomas*

First, we compared the clinicopathological features between 17 *H. pylori*-uninfected and -infected patients with SRCCs located within the mucosal layer. As shown in Table 1, the *H. pylori*-uninfected patients with mucosal SRCCs revealed male dominancy and a slightly younger age than the *H. pylori*-infected patients. The SRCCs in the *H. pylori*-uninfected patients tended to be located in the lower third of the stomach and its tumor size were significantly smaller than those in the *H. pylori*-infected patients. Although no difference was detected in blood type, family history of gastric cancer, or alcohol consumption, the prevalence of smokers was significantly higher among the *H. pylori*-uninfected patients (*p* = 0.02), although the Brinkman index was not different between the two groups.

*Next-generation sequencing of SRCC tissue samples*

DNA analysis by next-generation sequencing was performed in 16 samples from 14 patients (seven patients from each group) as shown in Table 2. We examined 10 diffuse-type gastric cancer associated genes (*CDH1, TP53, ARID1A, KRAS, PIK3CA, ERBB3, FBXW7, TGFBR1, RHOA, and MAK2K1*) referring to previous paper [11]. In addition, two DNA samples (one from an SRCC within the mucosal layer and one from a deeper PDA lesion) were extracted from two cases with invasive SRCC without *H. pylori* infection. In the control group, seven samples were collected from only mucosal SRCC with *H. pylori* infection. Therefore, in total, nine and seven DNA samples were extracted from the *H. pylori*-uninfected and -infected patients, respectively.

Finally, a single gene mutation was detected in each of five samples (Table 3, Figure 1). A *CDH1* mutation (frame shift indel) was detected only in one *H. pylori*-uninfected cancer lesion (case 6) (Figure 1). This mutation was found not only in the mucosal SRCC but also in the invasive PDA of that patient (Figure 2,3). A *TP53* mutation was detected in one SRCC without *H. pylori* infection (case 4). In the *H. pylori*-infected control group, mutations in *ARID1A* (case 11) and *TP53* (case 12) were detected in SRCCs (Figure 1). No mutation in *CDH1* was found in the control group. Furthermore, the C to A mutation, which is a characteristic smoking-induced mutation, was not found in any of the samples. On the other hand, we did not find somatic mutation in 7 genes (*KRAS, PIK3CA, ERBB3, FBXW7, TGFBR1, RHOA, and MAK2K1*) which associated somatic genomic alterations associated with the unique characteristics of sporadic diffuse gastric cancers [11]. (Figure 1)

**Discussion**

In the present study, we examined the clinical and genetic characteristics of SRCCs in patients without *H. pylori* infection. SRCCs in patients without *H. pylori* infection showed different features compared with those in patients
with *H. pylori* infection. Clinically, the *H. pylori*-uninfected patients with mucosal SRCCs showed male dominance and the tumor tissue tended to be located in the lower third of the stomach. These observations imply that *H. pylori*-uninfected SRCCs have distinct biological characteristics and probably have a different carcinogenetic pathway as compared with *H. pylori*-infected SRCCs.

Particular focus should be placed on the genetic alterations detected in SRCCs without *H. pylori* infection. Generally, diffuse-type cancers including SRCC are classified into the “genomically stable group” according to the four-subtype classification [12]. Under these conditions, *CDH1* have frequently been detected in SRCCs in patients with HDGC [13]. Moreover, E-cadherin, which is coded by *CDH1* gene, regulates signaling pathways leads to increase in cell proliferation, decrease in cell apoptosis followed by gastric cancer development [14]. However, in our study, the prevalence of mutations in *CDH1* was extremely low in SRCCs without *H. pylori* infection. This suggests that the carcinogenic pathway of SRCCs without *H. pylori* infection differs from that of SRCCs in patients with HDGC. The SRCC lesions found in *H. pylori*-uninfected patients seem to reflect not only a defect in cell-cell adhesion but also other neoplastic alterations.

Mutations in *TP53*, which are known as a representative driver mutation in gastric cancer carcinogenesis, were detected in SRCCs without *H. pylori* infection as well as those with *H. pylori* infection. This also strongly suggests that SRCCs in *H. pylori*-uninfected patients may be true neoplastic lesions. Previous reports have demonstrated that SRCC tissue gains an invasive ability after the mutation of *TP53* followed by conversion to PDA [15]. Accordingly, at least in a part of *H. pylori*-uninfected SRCC is a true neoplasm, and clinical features of SRCC without *H. pylori* infection may be different from that in HDGC. In the present study, we demonstrated the presence of similar genetic alterations between mucosal SRCC and invasive PDA in a *H. pylori*-uninfected patient, suggesting the progression of SRCC to invasive PDA. Indeed, we have diagnosed two cases with invasive SRCC without *H. pylori* infection (paper under submission). SRCC without *H. pylori* infection may have a malignant potential to invade into the submucosal layer and should be treated as a diffuse-type gastric cancer as described in the guidelines for treatment [16].

Notably, it should be emphasized that the prevalence of smokers was higher among the *H. pylori*-uninfected patients with SRCCs than among the *H. pylori*-infected patients. This finding is compatible with the previous report by Horiuchi et al. [8]. However, in our study concerning the genetic alterations in SRCC tissue samples, we could not find any C to A mutations, which are recognized as smoking-induced alterations, despite including samples from some heavy smokers in our analysis [17, 18]. Smoking may be a confounding factor as to the pathogenesis of SRCCs without *H. pylori* infection.

In addition to genetic mutations, gastric carcinogenesis may also be influenced by epigenomic alterations including gene methylation. Epstein–Barr virus (EB virus) infection, which induces several epigenetic alterations in host genes, may be another carcinogenic factor besides *H. pylori* infection [19]. However, it is supposed that *H. pylori* infection is essential for EB virus-induced carcinogenesis [20]. The pathogenesis of SRCCs without *H. pylori* infection remains unclear and should be clarified in future research.

This study has several limitations. The first limitation is the limited number of patients. To accurately evaluate the prevalence of any given genetic mutation, a large number of cases should be examined. In addition, we examined only ten genes in our cancer panel and we could not cover their complete exon sequences. In clinical practice, SRCCs without *H. pylori* infection are diagnosed when the lesions measure about 10 mm in diameter; therefore, it is difficult to extract high quality DNA from SRCC tissue. The second limitation is that DNA samples from control
lymphocytes were not analyzed. Therefore, we excluded disease-specific germline mutations and Japanese healthy germline mutations when searching the dbSNP 137 and TogoVar databases.

**Conclusions**

We have demonstrated the clinical features of patients with SRCCs without *H. pylori* infection and described some genetic alterations detected in these lesions. Our findings indicate that SRCCs without *H. pylori* should be treated as having a malignant potential similar to that for SRCCs occurring in the presence of *H. pylori* infection.

**Declarations**

**Availability of data and materials**

The datasets used and analyzed during the current study will be available from the corresponding author on reasonable request.

**Acknowledgements**

Quality check by Tapestation (Agilent, Santa Clara, CA, USA) was supported by the Program of the network-type Joint Usaga/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University. Next-generation sequencing was carried out at the Analysis Center of Life Science, Hiroshima University.

**Finding**

This study was funded by the Tsuchiya Memorial Medical Foundation(grant number 33-3). No additional external funding was received for this study.

**Author information**

**Affiliations**

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.

Mariko Kiso, Naoki Yorita, Naoko Nagasaki, Madina Abduwali, Yuich Hiyama, Shiro Oka, Kazuaki Chayama

Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.

Yuji Urabe

Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.

Masanori Ito
Department of Gastroenterology, Miyoshi Central Hospital, 10531 Higashisakeyamachi, Miyoshi, Hiroshima 728-8502 Japan.

Kazuhiko Masuda

Department of Endoscopy, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.

Tomoyuki Bodae, Takahiro Kotachie, Shinji Tanaka

Department of Gastroenterology, Chugoku Rosai Hospital, 1-5-1 Hirotagaya, Kure, 737-0193 Japan.

Kosaku Hata

**Contributions**

Conception and design of the study; Y.U., M.I., Analysis and interpretation of data; K.M., Y.U., K.M., Collection and assembly of data; K.M., T.B., T.K., K.H., N.Y., N.N., M.A., Y.H., S.O., S.T., Drafting of the article; K.M., Y.U., M.I., Critical revision of the article for important intellectual content; K.M., Final approval of the article; K.C.

**Corresponding author**

Correspondence to Yuji Urabe.

**Ethics declarations**

**Ethics approval and consent to participate**

All procedures were completed in accordance with the Declaration of Helsinki of 1964 and later versions. The Ethics Committee of Hiroshima University Hospital approved our study (E-1237). Informed consent was obtained from all patients by opt-out.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Additional information**

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Abbreviations**

SRCC: signet ring cell carcinoma

H. pylori: *Helicobacter pylori*
**HDGC**: hereditary diffuse gastric cancer

**PDA**: poorly differentiated adenocarcinoma

**FFPE**: formalin-fixed paraffin embedded

**EB virus**: Epstein–Barr virus

**References**

1. IARC Working Group Reports Volume 8. *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer.

2. Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of *Helicobacter pylori*-negative gastric cancer among Japanese. Helicobacter 2011;16:415-9.

3. Ono S, Kato M, Suzuki M, Ishigaki S, Takahashi M, Haneda M, et al. Frequency of *Helicobacter pylori*-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion 2012;86:59-65.

4. Kiso M, Yoshihara M, Ito M, Inoue K, Kato K, Nakajima S, et al. Characteristics of gastric cancer in negative test of serum anti-*Helicobacter pylori* antibody and pepsinogen test: a multicenter study. Gastric Cancer. 2017;20:764-71.

5. Yamamoto Y, Fujisaki J, Omae M, Hirasawa T, Igarashi M. *Helicobacter pylori*-negative gastric cancer: characteristics and endoscopic findings. Dig Endosc. 2015;27:551-61.

6. Horiuchi Y, Fujisaki J, Yamamoto N, Shimizu T, Miyamoto Y, Tomida H, et al. Biological behavior of the intramucosal *Helicobacter pylori*-negative undifferentiated-type early gastric cancer: comparison with *Helicobacter pylori*-positive early gastric cancer. Gastric Cancer. 2016;19:160-5.

7. Sugimoto S, Komatsu H, Morohoshi Y, Kanai T. Recognition of and recent issues in hereditary diffuse gastric cancer. J Gastroenterol. 2015;50:831-43.

8. Horiuchi Y, Fujisaki J, Ishizuka N, Omae M, Ishiyama A, Yoshio T, et al. Study on clinical factors involved in *Helicobacter pylori*-uninfected, undifferentiated-type early gastric cancer. Digestion. 2017;96:213-9.

9. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.

10. Peng Q, Vijaya Satya R, Lewis M BMC Genomics. 2015; 16: 589, https://www.agilent.com/cs/library/brochures/5991-8014EN.pdf.

11. Cho SY, Park JW, Liu Y, Park YS, Kim JH, Yang H, et al. Sporadic early-onset diffuse gastric cancers have high frequency of somatic CDH1 alterations, but low frequency of somatic RHOA mutations compared with late-onset cancers. Gastroenterology. 2017;153:536-549.

12. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-9.

13. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1:23-32.

14. Liu X, Chu KM. E-cadherin and gastric cancer: cause, consequence, and applications. Biomed Res Int. 2014;2014:637308.
15. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamachi H, et al. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut. 2012;61:344-53.

16. Ono H, Yao K, Fujishiro M, Oda I, Nimura S, Yahagi N, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc. 2016;28:3-15.

17. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst. 2000;92:803-11.

18. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Tanière P, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005; 65:5076-83.

19. Saju P, Murata-Kamiya N, Hayashi T, Senda Y, Nagase L, Noda S, et al. Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein-Barr virus. Nat Microbiol. 2016;1:16026.

20. Nishikawa J, Iizasa H, Yoshiyama H, Nakamura M, Saito M, Sasaki S, et al. The role of epigenetic regulation in Epstein-Barrvirus-associated gastric cancer. Int J Mol Sci. 2017;18.

Tables

Table 1. Comparison of Helicobacter pylori-uninfected and -infected mucosal signet ring cell carcinoma

|                      | HpU-SRCC (n = 17) | HpP-SRCC (n = 34) | p-value |
|----------------------|-------------------|-------------------|---------|
| Male/Female          | 15/2              | 14/20             | 0.004   |
| Age                  | 53.2 ± 11.4       | 58.2 ± 13.2       | n.s.    |
| Location             |                   |                   |         |
| Upper third          | 2 (11.8%)         | 0                 | n.s.    |
| Middle third         | 4 (23.5%)         | 24 (70.6%)        |         |
| Lower third          | 11 (64.7%)        | 10 (29.4%)        |         |
| Size                 | 9.1 ± 5.3         | 16.0 ± 11.7       | 0.03    |
| Blood type (A/B/O/AB)| 8/1/5/3           | 16/4/9/5          | n.s.    |
| Family history* of  | 6/13 (46%)        | 7/23 (30%)        | n.s.    |
| gastric cancer       |                   |                   |         |
| Alcohol              | 10/17 (59%)       | 16/26 (62%)       | n.s.    |
| Smoking              | 11/17 (65%)       | 6/26 (23%)        | 0.02    |
| Brinkman Index       | 563.6             | 526.7             |         |

HpU-SRCC: Helicobacter pylori-uninfected signet-ring cell carcinoma, HpP-SRCC: Helicobacter pylori positive (infected) signet-ring cell carcinoma, n.s.: not significant

* Family History: relative within the 3-degree relationship

With drinking history, drink alcohol 21.6 g/day or more and drink more than 3 days a week as a drinker. And with smoking history, defined including smoking in present and in the past.
### Table 2. Clinical characteristic of signet ring cell carcinoma subjected to gene analysis

| Pri | Age | Sex | Position     | Size (mm) | Macroscopic type | Histology | Depth | Period* |
|-----|-----|-----|--------------|-----------|------------------|-----------|-------|---------|
| ve  | 42  | M   | antrum       | 8         | 0-IIc            | Sig       | M     | 8y      |
| ve  | 65  | M   | angular region | 5        | 0-IIc            | Sig       | M     | 7y      |
| ve  | 41  | M   | antrum       | 20        | 0-IIc            | Sig       | M     | 6y      |
| ve  | 40  | M   | antrum       | 5         | 0-IIc            | Sig       | M     | 3y      |
| ve  | 64  | M   | upper body   | 20        | SMT              | Por2>Sig  | SS    | 3y      |
| ve  | 36  | M   | fornix       | 30        | 0-IIc            | Por1>Sig  | SE    | 17y     |
| ve  | 49  | M   | antrum       | 10        | 0-IIc            | Sig       | M     | 3y      |
| re  | 50  | F   | middle body  | 5         | 0-IIc            | Sig       | M     | 7y      |
| re  | 52  | F   | angular region | 15       | 0-IIc            | Sig       | M     | 8y      |
| re  | 55  | F   | angular region | 20       | 0-IIc            | Sig       | M     | 8y      |
| re  | 57  | F   | antrum       | 10        | 0-IIc            | Sig       | M     | 7y      |
| re  | 40  | M   | angular region | 8        | 0-IIc            | Sig       | M     | 7y      |
| re  | 46  | M   | antrum       | 10        | 0-IIc            | Sig       | M     | 7y      |
| re  | 68  | M   | angular region | 25       | 0-IIc            | Sig       | M     | 7y      |

Sig: signet ring cell carcinoma, por1: Poorly differentiated adenocarcinoma solid type, por2: Poorly differentiated adenocarcinoma non-solid type, M: mucosa, SS: subserosa, SE: serosa

*The period among paraffin embedding (years)

### Table 3. Gene mutation detected in 16 samples
| Gene   | Chrom | Position | Ref Allele | Alt Allele | Allele Frequency | Read depth | Function Class | Codon | AA     |
|--------|-------|----------|------------|------------|------------------|------------|----------------|-------|--------|
| TP53   | 17    | 7579542  | C          | G          | 0.39             | 251        | MISSENSE       |       | D10H   |
| CDH1   | 16    | 68853327 | TG         | T          | 0.51             | 49         |                |       |        |
| CDH1   | 16    | 68853327 | TG         | T          | 0.57             | 69         |                |       |        |
| ARID1A | 1     | 27106333 | G          | A          | 0.571            | 105        | MISSENSE       | Gtc/Act | V1765I |
| TP53   | 17    | 7579705  | C          | T          | 0.48             | 123        | MISSENSE       | Gtt/Att | V31I   |

Sig: signet ring cell carcinoma, por1: Poorly differentiated adenocarcinoma solid type

Figures

Figure 1.  

【mutation profiling】

Number of mutation

Sig: signet ring cell carcinoma, por1: Poorly differentiated adenocarcinoma solid type
Mutational landscapes of Seven SRCCs without Helicobacter pylori infection, and seven H. pylori-positive SRCCs. Gastric signet ring cell carcinoma (SRCCs) tissues, paired non-cancerous tissues, from Seven SRCCs without Helicobacter pylori (H. pylori) infection, and seven H. pylori-positive SRCCs were subjected to the targeted panel for 10 genes. The Upper bar-graph shows the number of somatic mutations per sample. The Lower panel shows the type of mutation of each gene. Genes reported SRCC-associated genes in previous paper. First line shows H. pylori-infect, second line shows smoking status, and from 3th to 12th line shows the type of mutation of each gene. Blue panels shows H. pylori-infected cases, brown panels shows present or current smoker, light-brown panels shows non-smoker, red panels shows frameshift indels or nonsense mutations, and yellow panels shows missence mutations.

Figure 2.

Endoscopic features of case 6 (a 36-year-old man). Endoscopic examination showed no atrophic changes in the background mucosa [a]. A depressed lesion measuring approximately 30 mm in diameter was observed in the fornix [b].
Figure 3

Histological features of case 6. A depressed lesion was found in the center of the section (a) and the low magnitude feature [red box in (a)] was demonstrated in (b). The histologic features of a higher magnitude mucosal signet ring cell carcinoma (yellow box) and a poorly differentiated adenocarcinoma in the deep invasive portion (blue box) are shown in (c) and (d), respectively (hematoxylin and eosin staining).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supportingfile1parameter.docx